Efficacy and Safety of Tolterodine Extended Release and Dutasteride in Male Overactive Bladder Patients With Prostates >30 Grams

Urology

Volumn 75, Issue 5, 2010, Pages 1144-1148

  Chung, Doreen E ^a   Te, Alexis E ^a   Staskin, David R ^b   Kaplan, Steven A ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DUTASTERIDE; TOLTERODINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG INDICATION; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; EVENING DOSAGE; HUMAN; INTERNATIONAL PROSTATE SYMPTOM SCORE; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; MALE SEXUAL DYSFUNCTION; ORGAN WEIGHT; OVERACTIVE BLADDER; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUALITY OF LIFE; SEXUAL DYSFUNCTION; TREATMENT RESPONSE; URINARY FREQUENCY; URINE FLOW RATE; XEROSTOMIA;

AZASTEROIDS; BENZHYDRYL COMPOUNDS; CRESOLS; DELAYED-ACTION PREPARATIONS; HUMANS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; ORGAN SIZE; PHENYLPROPANOLAMINE; PROSTATE; PROSTATISM; URINARY BLADDER, OVERACTIVE;

EID: 77951666879     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2009.12.010     Document Type: Article

References (30)

1. Irwin D., Milsom I., Hunskaar S., et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 50 (2006) 1306-1314
2. Sexton C., Coyne K., Kopp Z., et al. The overlap of storage, voiding and postmicturition symptoms and implications for treatment seeking in the USA, UK and Sweden: EpiLUTS. BJU Int 103 (2009) 12-33
3. Hyman M., Groutz A., and Blaivas J. Detrusor instability in men: correlation of lower urinary tract symptoms with urodynamic findings. J Urol 166 (2001) 550-552
4. Laniado M., Ockrim J., Marronaro A., et al. Serum prostate specific antigen to predict the presence of bladder outlet obstruction in men with urinary symptoms. BJU Int 94 (2004) 1283-1286
5. Abrams P., Cardozo L., Fall M., et al. The standardization of terminology in lower urinary tract function: report from the standardization sub-committee of the International Continence Society. Urology 61 (2003) 37-49
6. Abdel-Aziz K., and Lemack G. Overactive bladder in the male patient: bladder, outlet, or both?. Curr Urol Rep 3 (2002) 445-451
7. de Groat W. A neurologic basis for the overactive bladder. Urology 50 (1997) 36-52
8. Brading A., and Turner W. The unstable bladder: towards a common mechanism. Br J Urol 73 (1994) 3-8
9. Drake M., Mills I., and Gillespie J. Model of peripheral autonomous modules and a myovesical plexus in normal and overactive bladder function. Lancet 358 (2001) 401-403
10. Blake-James B., Rashidian A., Ikeda Y., et al. The role of anticholinergics in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a systematic review and meta-analysis. BJU Int 99 (2007) 85-96
11. Chapple C., and Roehrborn C. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol 49 (2006) 651-659
12. Knutson T., Edlund C., Fall M., et al. BPH with coexisting overactive bladder dysfunction-an everyday urological dilemma. Neurourol Urodyn 20 (2001) 237-247
13. Roehrborn C., McConnell J., Barry M., et al. Guideline on the Management of Benign Prostatic Hypertrophy (BPH): AUA Clinical Guidelines (2006)
14. Chapple C. Pharmacological therapy of benign prostatic hyperplasia/lower urinary tract symptoms: an overview for the practising clinician. BJU Int 94 (2004) 738-744
15. McGuire E. Neuromuscular dysfunction of the lower urinary tract. In: Walsh P., Gittes R., Perlmutter A., et al. (Eds). Campbell's Urology (1986), W. B. Saunders, Philadelphia, PA
16. Kaplan S., Roehrborn C., Rovner E., et al. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA 296 (2006) 2319-2328
17. Kaplan S., Walmsley K., and Te A. Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol 179 (2008) S82-S85
18. Abrams P., Kaplan S., De Koning Gans H., et al. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol 175 (2006) 999-1004
19. Lee J., Kim H., Lee S., et al. Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. BJU Int 94 (2004) 817-820
20. Roehrborn C., Kaplan S., Jones J., et al. Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effect of prostate size. Eur Urol 55 (2009) 472-481
21. Roehrborn C., Kaplan S., Kraus S., et al. Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB. Urology 72 (2008) 1061-1607
22. Coyne K., Matza L., Kopp Z., Abrams P., et al. The validation of the patient perception of bladder condition (PPBC): a single-item global measure for patients with overactive bladder. Eur Urol 49 (2006) 1079-1086
23. Irwin D., Milsom I., Kopp Z., et al. Prevalence, severity, and symptom bother of lower urinary tract symptoms among men in the EPIC study: impact of overactive bladder. Eur Urol 56 (2009) 14-20
24. Coyne K., Sexton C., Irwin D., et al. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. BJU Int 101 (2008) 1388-1395
25. Emberton M., Neal D., Black N., et al. The effect of prostatectomy on symptom severity and quality of life. Br J Urol 77 (1996) 233-247
26. Housami F., and Abrams P. Persistent detrusor overactivity after transurethral resection of the prostate. Curr Urol Rep 9 (2008) 284-290
27. Johnson T., Jones K., Williford W., et al. Changes in nocturia from medical treatment of benign prostatic hyperplasia: secondary analysis of the department of veterans affairs cooperative study trial. J Urol 170 (2003) 145-148
28. Chapple C., Herschorn S., Abrams P., et al. Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers. Eur Urol 56 (2009) 534-541
29. Van Venrooij G., Van Melick H., Eckhardt M., et al. Correlations of urodynamic changes with changes in symptoms and well-being after transurethral resection of the prostate. J Urol 168 (2002) 605-609
30. MacDiarmid S., Peters K., Chen A., et al. Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized double-blind placebo-controlled study. Mayo Clin Proc 83 (2008) 1002-1010